Clinical Trials Browser

Interventional × Erlotinib Hydrochloride × Tumor-Agnostic × Clear all

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT01010945 2024-11-21

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Phase 1 Completed

Adenocarcinoma

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05904457 2023-06-15

BRISK

Phase 2 Unknown

Neoplasm Metastasis, Neoplasms

NCT02942095 2023-04-18

Study of Ixazomib and Erlotinib in Solid Tumors

Phase 1 Completed

Neoplasm Metastasis

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT01636908 2021-04-15

ICK

Phase NA Completed

Neoplasms

NCT02714530 2021-03-30

ThoRaT

Phase 2 Terminated

Neoplasms

NCT01197170 2021-01-22

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

Phase 1 Completed

Neoplasm Metastasis

NCT01190241 2020-11-20

TSAP

Phase NA Terminated

Neoplasm Metastasis

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Neoplasms

NCT01518621 2019-03-13

RadEr

Phase 2 Terminated

Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT01284335 2019-01-10

A Safety Study in Participants With Advanced Solid Tumors

Phase 1 Terminated

234 enrolled 23 charts

Neoplasm Metastasis

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1/2 Terminated

15 enrolled 11 charts

Neoplasms

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

Neoplasms

NCT00369512 2017-05-30

RAD0503

Phase 2 Completed

15 enrolled 9 charts

Carcinoma, Squamous Cell, Neoplasms

NCT01482377 2017-01-27

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Phase 1 Completed

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

Neoplasms

NCT00737243 2016-08-17

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Phase 2 Completed

289 enrolled 5 charts

Carcinoma

NCT00207077 2015-10-28

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00585377 2015-09-24

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

Phase 2 Completed

50 enrolled 7 charts

Neoplasms

NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Phase 2 Terminated

13 enrolled 8 charts

Carcinoma, Squamous Cell

NCT00895687 2015-07-13

Study of Erlotinib in Combination With Bortezomib

Phase 1 Completed

Neoplasm Metastasis

NCT00903734 2015-07-13

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Phase 1 Completed

Neoplasm Metastasis

NCT00476476 2015-05-07

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Phase 2 Completed

41 enrolled 7 charts

Carcinoma, Squamous Cell

NCT01727869 2015-04-06

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Phase 1 Completed

Neoplasms

NCT00884845 2014-03-26

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Phase 1 Completed

Neoplasms

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Phase 2 Completed

60 enrolled 6 charts

Neoplasms, Unknown Primary

NCT00591383 2012-07-19

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Phase 1 Unknown

Neoplasms

NCT00611468 2011-08-22

Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

Phase 1 Completed

29 enrolled 13 charts

Neoplasm Metastasis

NCT00193622 2010-09-17

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Phase 2 Completed

Neoplasms, Unknown Primary